Abstract

ObjectiveTo characterize co-deletion of chromosome 1p/19q and IDH1/2 mutation in Chinese brain tumor patients and to assess their associations with clinical features.MethodsIn a series of 528 patients with gliomas, pathological and radiological materials were reviewed. Pathological constituents of tumor subsets, incidences of 1p/19q co-deletion and IDH1/2 mutation in gliomas by regions and sides in the brain were analyzed.ResultsOverall, 1p and 19q was detected in 339 patients by FISH method while the sequence of IDH1/2 was determined in 280 patients. Gliomas of frontal, temporal and insular origin had significantly different pathological constituents of tumor subsets (P<0.001). Gliomas of frontal origin had significantly higher incidence of 1p/19q co-deletion (50.4%) and IDH1/2 mutation (73.5%) than those of non-frontal origin (27.0% and 48.5%, respectively) (P<0.001), while gliomas of temporal origin had significantly lower incidence of 1p/19q co-deletion (23.9%) and IDH1/2 mutation (41.7%) than those of non-temporal origin (39.9% and 63.2%, respectively) (P = 0.013 and P = 0.003, respectively). Subgroup analysis confirmed these findings in oligoastrocytic and oligodendroglial tumors, respectively. Although the difference of 1p/19q co-deletion was not statistically significant in temporal oligodendroglial tumors, the trend was marginally significant (P = 0.082). However, gliomas from different sides of the brain did not show significant different pathological constituents, incidences of 1p/19q co-deletion or IDH1/2 mutation.ConclusionPreferential distribution of pathological subsets, 1p/19q co-deletion and IDH1/2 mutation were confirmed in some brain regions in Chinese glioma patients, implying their distinctive tumor genesis and predictive value for prognosis.

Highlights

  • Glioma is the most common primary intracranial tumor [1]

  • The patients’ ages ranged from 14 to 68 years old with a mean of 41.5611.6 years. This series of 528 gliomas consisted of 108 astrocytoma World Health Organization (WHO) grade II (A), 45 anaplastic astrocytoma WHO grade III (AA), 88 primary glioblastoma WHO grade IV (G), 80 oligodendroglioma WHO grade II (O), 37 anaplastic oligodendroglioma WHO grade III (AO), 99 oligoastrocytoma WHO grade II (OA) and 71 anaplastic oligoastrocytoma WHO grade III (AOA)

  • We reviewed a series of 528 cases of gliomas retrospectively and compared regional constituents of pathological subsets, regional incidences of 1p/19q co-deletion and IDH1/2 mutation

Read more

Summary

Introduction

According to 2007 WHO Classification of Tumors of the Central Nervous System [2], gliomas consist of all brain tumors that are of glial cell origin, accounting for almost 80% of primary malignant brain tumors [3]. They are graded according to biological behavior of the tumors. Co-deletion of 1p and 19q is associated with longer progression-free time and longer median survival time, representing an independent prognostic factor in anaplastic oligodendroglial tumors (WHO grade III) [5,6,7,8]. 1p/19q co-deletion predicts a longer radiographic response to temozolomide and is associated with both superior overall survival and progression-free survival in low-grade oligodendroglial tumors [9,10,11,12]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call